Abstract
To establish equivalent doses of four non-steroidal anti-inflammatory drugs (NSAID) in normotensive and hypertensive rats using inhibition of the fall in blood pressure produced by the injection of arachidonic acid as the measure of equivalence. An experimental study using two rat models of hypertension and their normotensive controls. Two rat models of hypertension (spontaneously hypertensive rats and two-kidney, one clip rats) and their normotensive controls were studied. The change in blood pressure after intravenous injection of arachidonic acid was measured in anaesthetized rats. Blood pressure was measured from a carotid artery cannula, attached to a pen-recorder. Dose-response curves for the effect of arachidonic acid were established in each type of rat, then the effects of different doses of four NSAID (indomethacin, piroxicam, naproxen and sulindac) on these responses were measured. Arachidonic acid produced a dose-dependent fall in blood pressure in all rats. However, both types of hypertensive rats sustained a larger fall in blood pressure for a given dose of arachidonic acid than did the normotensive controls. Doses of NSAID were found that inhibited this response in Wistar rats. However, the doses of NSAID that were equivalent in normotensive rats were not equivalent in either type of hypertensive rat; indomethacin had a greater inhibitory effect. As far as could be established, this was not due to differences in the metabolism of the NSAID between normotensive and hypertensive rats. The arachidonic acid response can be used as a method of establishing equivalent doses of NSAID in normotensive and hypertensive rats. Hypertensive rats appear to be more sensitive to the effects of arachidonic acid than normotensive rats, independent of the model of hypertension. Doses of NSAID that are equivalent in normotensive rats are not equivalent in hypertensive rats. Indomethacin is more effective in attenuating the effect of arachidonic acid, possibly due to actions other than inhibition of cyclo-oxygenase.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
